98%
921
2 minutes
20
Purpose: To evaluate whether a second biopsy, following a first diagnostic failure on blastocysts tested for preimplantation genetic testing for monogenic diseases (PGT-M), allows to obtain genetic diagnosis and to what extent this procedure can influence clinical pregnancy and live birth rates compared to the PGT-M process with a successful genetic diagnosis from the first biopsy.
Methods: Embryos from women who underwent PGT-M in an infertility centre and who had been transferred after two biopsies for genetic analysis (n = 27) were matched in a 1:1 ratio accordingly to women's age (± 1 year) and fertility status (fertile vs infertile), as well as with the study period, with embryos who were transferred after receiving a conclusive PGT result straight after the first biopsy (n = 27). The main evaluated outcome was clinical pregnancy rate following embryo transfers in which healthy embryos were transferred after only one biopsy and those in which an embryo was transferred after being re-biopsied. Live birth rate was the secondary outcome.
Results: Clinical pregnancy rate was 52% (95% CI: 34-69) following the transfer of a single-biopsy blastocyst and 30% (95% CI: 16-48) following the transfer of a re-biopsied blastocyst. The likelihood to have a healthy baby was 33% (95% CI: 19-52) following the transfer of a blastocyst biopsied once and 22% (95% CI: 11-41) following the transfer of a re-biopsied blastocyst.
Conclusions: The re-biopsy intervention seems to considerably reduce the pregnancy potential of a blastocyst. However, a greater sample size is necessary to clarify this issue definitively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11143113 | PMC |
http://dx.doi.org/10.1007/s10815-024-03078-w | DOI Listing |
JAMA
September 2025
Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands.
Importance: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks.
Objective: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth.
JAMA Pediatr
September 2025
Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia.
Importance: For the first time in nearly 2 decades, the US infant mortality rate has increased, coinciding with a rise in overdose-related deaths as a leading cause of pregnancy-associated mortality in some states. Prematurity and low birth weight-often linked to opioid use in pregnancy-are major contributors.
Objective: To assess the health and economic impact of perinatal opioid use disorder (OUD) treatment on maternal and postpartum health, infant health in the first year of life, and infant long-term health.
JAMA Netw Open
September 2025
Yale School of Medicine, New Haven, Connecticut.
Importance: Approximately 35% of individuals seeking abortion care use Medicaid for health insurance. Although the Hyde Amendment restricts use of federal funds for most abortions, states can supplement coverage using state funds. Understanding the scope of abortion coverage across states and potential barriers to access may help address health care inequities and inform interventions.
View Article and Find Full Text PDFJ Ultrasound Med
September 2025
Department of Clinical Analysis, Federal University of Santa Catarina (UFSC), Florianópolis, Brazil.
Objectives: To evaluate the performance of artificial intelligence (AI)-based models in predicting elevated neonatal insulin levels through fetal hepatic echotexture analysis.
Methods: This diagnostic accuracy study analyzed ultrasound images of fetal livers from pregnancies between 37 and 42 weeks, including cases with and without gestational diabetes mellitus (GDM). Images were stored in Digital Imaging and Communications in Medicine (DICOM) format, annotated by experts, and converted to segmented masks after quality checks.
J Ultrasound Med
September 2025
Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Tremendous advances in ultrasound equipment and knowledge have expanded possibilities for the first trimester detailed ultrasound examination. Recommendations from national organizations to offer this service to patients with indications, coupled with recent modifications for dual use of the current procedural terminology code 76811 during pregnancy, will result in increased demand from patients and referring physicians. While proper reimbursement may motivate healthcare professionals to incorporate the first trimester detailed ultrasound examination into their practice and raise the standards of care in the first trimester, it can also be a challenging transition.
View Article and Find Full Text PDF